– UK, London – Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, today announced the appointment of Laurent Audoly to its Board as a Non-Executive Director.
“We are delighted to welcome Laurent to our Board. Laurent has a wealth of experience in the biopharmaceutical sector in science and business management, bringing innovative new medicines to patients and creating value for shareholders. Laurent’s insights will be invaluable as we continue to refine the company’s strategy and work towards upcoming milestones for our multicell therapies and in vivo gene delivery platform.” said CEO, Joe Dupere.
About Laurent Audoly
Laurent Audoly is a pharma and biotech entrepreneur and senior executive. He is co-founder, CEO, and Chairman of Parthenon Therapeutics, a precision oncology biotech based in Boston. He has also led corporate and R&D functions across both pharma and biotech in the US and Europe, including as CEO of Kymera Therapeutics and Head of R&D at Pierre Fabre Pharmaceuticals, as well as scientific and business leadership positions at Pfizer, Merck, and Pieris. Laurent Audoly has completed transactions worth more than $3 billion and raised more than $250 million, as well as contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities.
Laurent Audoly is an inventor and has authored over 70 papers and patents. He has led and contributed to the identification and development of seven novel medicines including both biologics and small molecules (Xeljanz, Hemangiol, Javlor, Renflexis, Brenzys, Ontruzant, and Hadlima), addressing unmet medical needs across multiple disease areas that generate more than $3 billion in annual sales.
Laurent will work alongside other Board members and Ixaka’s leadership team on strategy, business development, expansion of the business in the United States, and advancement of Ixaka’s proprietary technologies – concentrated multicell therapies and targeted in vivo gene delivery therapeutics.
Laurent Audoly commented: “Ixaka has an exciting approach to cell and gene therapies, high-potential new therapy candidates and a technology platform that can be applied to a broad range of poorly treated diseases. Working with Joe and the rest of the team is a great opportunity and I look forward to supporting them in developing the business and driving Ixaka’s R&D programs forward.”
Laurent gained a Ph.D. in Pharmacology from Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University, where he was the recipient of an American Heart Association Fellowship.
About Ixaka
Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease.
Ixaka’s proprietary technologies enhance the naturally therapeutic power of cells by increasing the presence of curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their restorative effect.
Ixaka’s technologies – concentrated multi-cell therapies and nanoparticle therapeutics – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological, and ocular diseases, and genetic disorders.
Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain, and Paris, France, and additional manufacturing capability in Frankfurt, Germany.
For more information: https://www.ixaka.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
